Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keytruda/Lenvima CRL To Give Roche More Space In 1L HCC?

But Phase III Is Already Enrolled

Executive Summary

Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.

You may also be interested in...



AstraZeneca's Imfinzi/Tremelimumab Combo Conquers HIMALAYA

After the combination's success in the non-small cell lung cancer POSEIDON study, AstraZeneca's Imfinzi and tremelimumab could now be on the way to approval as a first-line treatment for hepatocellular carcinoma.

Earlier Use of Exelixis/Ipsen's Cabozantinib Hits Hurdle In Liver Cancer

Exelixis/Ipsen’s novel combination of cabozantinib and atezolizumab has produced mixed top-line results from the Phase III COSMIC-312 study, and although the companies are pressing ahead with further analyses, the doublet may struggle to compete in the first-line advanced liver cancer setting.

Merck & Co.’s Keytruda Stakes Another Adjuvant Flag, In RCC

Adjuvant renal cell carcinoma is a potentially lucrative indication for any checkpoint inhibitor; Merck & Co. flagship Keytruda is the first to demonstrate benefit in a Phase III study, although rivals are in pursuit.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel